Aytu BioScience

125 articles with Aytu BioScience

• 

  Axsome and Aytu's Positive Day with the FDA

  4/19/2022

  Axsome Therapeutics received good news regarding its NDA for AXS-05, a treatment for depression, and Aytu BioScience received Fast Track designation for its VEDS treatment.

• Aytu BioPharma to Participate in the 34th Annual Roth Conference

  3/8/2022

  Aytu BioPharma, Inc. announced that Mark Oki, chief financial officer, and Greg Pyszczymuka, chief commercial officer of Aytu BioPharma, will participate in a fireside chat during the 34th Annual Roth Conference on Tuesday, March 15, 2022 at 2:00 p.m. PT.

• Aytu BioPharma Announces Closing of $7.6 Million Registered Offering

  3/7/2022

  Aytu BioPharma, Inc. announced the closing of its previously announced underwritten offering of 3,030,000 shares of its common stock, pre-funded warrants to purchase up to 3,030,000 shares of its common stock, and common warrants to purchase up to 6,666,000 shares of its common stock resulting in gross proceeds of $7.6 million, assuming none of the accompanying common warrants issued in the Offering are exercised.

• Aytu BioPharma Reports First Quarter 2022 Financial Results

  11/15/2021

  Aytu BioPharma, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, reported financial results for its fiscal first quarter 2022 ended September 30, 2021.

• Aytu BioPharma to Present at Upcoming June Investor Conferences

  5/25/2021

  Aytu BioPharma, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced that Josh Disbrow, Chairman and Chief Executive Officer, will present at two upcoming investor conferences in June:

• Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021

  5/10/2021

  Aytu BioPharma, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced that it will host a conference call and live webcast on Monday, May 17, 2021, at 4:30 p.m. ET to report its financial results for the fiscal third quarter ended March 31, 2021 and review recent accomplishments.

• Aytu BioScience Announces Close of Merger with Neos Therapeutics

  3/22/2021

  Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced the closing of its merger with Neos Therapeutics.

• Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

  3/10/2021

  The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time

• Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients

  3/8/2021

  Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from a first in-human, open label, clinical trial in SARS-CoV-2 patients has been released.

• Aytu BioScience to Present at Upcoming March Investor Conferences

  2/24/2021

  Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer will present at three upcoming investor conferences in March: Cowen 41 st Annual Healthcare Conference :

• Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year

  2/11/2021

  Announced definitive merger agreement with Neos Therapeutics, creating a combined $100 million revenue specialty pharmaceutical company Q2 Consumer Health division revenue reaches an all-time high of $7.9 million Q2 Rx division revenue up 24% sequentially

• Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021

  2/10/2021

  Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc.

• Aytu BioScience to Report Second Fiscal 2021 Results and Provide Business Update on Thursday, February 11, 2021

  2/4/2021

  Aytu BioScience, Inc. (NASDAQ:AYTU) , a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal second quarter ended December 31, 2020 on February 11, 2021, at 4:30 p.m. ET.

• Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients

  12/28/2020

  Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced the completion of the safety study evaluating the Healight; ultraviolet A light catheter technology.

• Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

  12/15/2020

  Aytu BioScience, Inc. (NASDAQ:AYTU), , a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closing of its previously announced underwritten public offering of 4,791,667 shares of common stock of the Company, which includes the full exercise of the underwriters option to purchase an additional 625,000 shares

• Aytu BioScience to Present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET

  12/14/2020

  Aytu BioScience, Inc. (NASDAQ:AYTU) , a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that management will present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET.

• Aytu BioScience Announces $10.0 Million Bought Deal Offering

  12/10/2020

  Aytu BioScience, Inc. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts and commissions.

• Aytu BioScience Increases Previously Announced Bought Deal Offering to $25.0 Million

  12/10/2020

  Aytu BioScience, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 4,166,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts and commissions.

• Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company

  12/10/2020

  Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company

• Aytu BioScience Announces Fiscal Q1 2021 Net Revenue of $13.5 Million, an Increase of 839% Year-Over-Year

  11/12/2020

  Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs reported financial results for its fiscal first quarter 2021, for the three month period ending September 30, 2020.